Emergent Biosolutions (NYSE:EBS) issued its quarterly earnings data on Thursday. The biopharmaceutical company reported $0.55 EPS for the quarter, missing the consensus estimate of $0.62 by ($0.07), Briefing.com reports. The company had revenue of $173.70 million during the quarter, compared to analysts’ expectations of $185.16 million. Emergent Biosolutions had a return on equity of 15.09% and a net margin of 16.55%. The business’s revenue for the quarter was up 16.3% compared to the same quarter last year. During the same period last year, the company earned $0.73 earnings per share.
Shares of EBS traded up $0.98 on Friday, reaching $64.84. 714,919 shares of the company’s stock traded hands, compared to its average volume of 342,187. The company has a current ratio of 5.59, a quick ratio of 4.15 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $3.02 billion, a price-to-earnings ratio of 34.13, a PEG ratio of 1.23 and a beta of 1.23. Emergent Biosolutions has a 52-week low of $36.38 and a 52-week high of $67.24.
Several analysts have recently commented on EBS shares. Chardan Capital increased their price objective on Emergent Biosolutions from $60.00 to $66.00 and gave the stock a “buy” rating in a research note on Tuesday, September 4th. Zacks Investment Research downgraded Emergent Biosolutions from a “buy” rating to a “hold” rating in a research note on Monday, August 20th. Cantor Fitzgerald set a $68.00 price objective on Emergent Biosolutions and gave the stock a “buy” rating in a research note on Tuesday, September 11th. Argus increased their price objective on Emergent Biosolutions to $70.00 and gave the stock an “average” rating in a research note on Tuesday, September 11th. They noted that the move was a valuation call. Finally, Cowen reissued a “hold” rating and issued a $49.00 price objective on shares of Emergent Biosolutions in a research note on Wednesday, August 29th. Four analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Emergent Biosolutions has an average rating of “Buy” and an average target price of $65.00.
In other Emergent Biosolutions news, CEO Daniel Abdun-Nabi sold 1,319 shares of the stock in a transaction on Monday, September 17th. The stock was sold at an average price of $65.00, for a total transaction of $85,735.00. Following the completion of the transaction, the chief executive officer now directly owns 194,787 shares of the company’s stock, valued at $12,661,155. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Adam Havey sold 22,996 shares of the stock in a transaction on Tuesday, October 16th. The shares were sold at an average price of $61.06, for a total value of $1,404,135.76. Following the transaction, the executive vice president now directly owns 36,079 shares of the company’s stock, valued at $2,202,983.74. The disclosure for this sale can be found here. Insiders have sold 187,522 shares of company stock valued at $11,293,890 over the last ninety days. 16.50% of the stock is currently owned by company insiders.
Emergent Biosolutions Company Profile
Emergent BioSolutions Inc focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases.
Recommended Story: What is the Dividend Aristocrat Index?
Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.